FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034621471> ?p ?o ?g. }

• W2034621471 endingPage "1301" @default.
• W2034621471 startingPage "1301" @default.
• W2034621471 abstract "5α-Reductase inhibitors (5ARIs) are widely used for benign prostatic hyperplasia despite controversy regarding potential risk of high-grade prostate cancer with use. Furthermore, the effect of 5ARIs on progression and prostate cancer death remains unclear.To determine the association between 5ARI use and development of high-grade or lethal prostate cancer.Prospective observational study of 38,058 men followed up for prostate cancer diagnosis and outcomes between 1996 and 2010 in the Health Professionals Follow-up Study.Use of 5ARIs between 1996 and 2010.Cox proportional hazards models were used to estimate risk of prostate cancer diagnosis or development of lethal disease with 5ARI use, adjusting for possible confounders including prostate specific antigen testing.During 448,803 person-years of follow-up, we ascertained 3681 incident prostate cancer cases. Of these, 289 were lethal (metastatic or fatal), 456 were high grade (Gleason sum [GS] 8-10), 1238 were GS 7, and 1600 were low grade (GS 2-6). A total of 2878 (7.6%) men reported use of 5ARIs between 1996 and 2010. After adjusting for confounders, men who reported ever using 5ARIs over the study period had a reduced risk of overall prostate cancer (hazard ratio [HR], 0.77; 95% CI, 0.65-0.91). 5ARI users had a reduced risk of GS 7 (HR, 0.67; 95% CI, 0.49-0.91) and low-grade (GS 2-6) prostate cancer (HR, 0.74; 95% CI, 0.57-0.95). 5ARI use was not associated with risk of high-grade (GS 8-10) prostate cancer (HR, 0.97; 95% CI, 0.64-1.46) or lethal disease (HR, 0.99; 95% CI, 0.58-1.69). Increased duration of use was associated with significantly lower risk of overall prostate cancer (HR for 1 year of additional use, 0.95; 95% CI, 0.92-0.99), localized (HR, 0.95; 95% CI, 0.90-1.00), and low-grade disease (HR, 0.92; 95% CI, 0.85-0.99). There was no association for lethal, high-grade, or grade 7 disease.While 5ARI use was not associated with developing high-grade or lethal prostate cancer, it was associated with a reduction in low-grade, GS 7, and overall prostate cancer. Because the number of patients with high-grade or lethal prostate cancer in our cohort was limited, we cannot rule out potential risk of harm with 5ARI use." @default.
• W2034621471 created "2016-06-24" @default.
• W2034621471 creator A5017446229 @default.
• W2034621471 creator A5024094716 @default.
• W2034621471 creator A5038373228 @default.
• W2034621471 creator A5041987495 @default.
• W2034621471 creator A5049753330 @default.
• W2034621471 creator A5067413533 @default.
• W2034621471 creator A5071763026 @default.
• W2034621471 creator A5071993333 @default.
• W2034621471 creator A5072330763 @default.
• W2034621471 creator A5086101616 @default.
• W2034621471 date "2014-08-01" @default.
• W2034621471 modified "2023-10-16" @default.
• W2034621471 title "5α-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer" @default.
• W2034621471 cites W1837385886 @default.
• W2034621471 cites W1997348862 @default.
• W2034621471 cites W1998455906 @default.
• W2034621471 cites W2002395040 @default.
• W2034621471 cites W2012358309 @default.
• W2034621471 cites W2012608816 @default.
• W2034621471 cites W2023481449 @default.
• W2034621471 cites W2031986837 @default.
• W2034621471 cites W2042589569 @default.
• W2034621471 cites W2052163549 @default.
• W2034621471 cites W2071679886 @default.
• W2034621471 cites W2074003955 @default.
• W2034621471 cites W2078162311 @default.
• W2034621471 cites W2096544053 @default.
• W2034621471 cites W2096802466 @default.
• W2034621471 cites W2106058419 @default.
• W2034621471 cites W2110708036 @default.
• W2034621471 cites W2113720631 @default.
• W2034621471 cites W2121759271 @default.
• W2034621471 cites W2123411838 @default.
• W2034621471 cites W2123918450 @default.
• W2034621471 cites W2124215421 @default.
• W2034621471 cites W2124517950 @default.
• W2034621471 cites W2131125612 @default.
• W2034621471 cites W2142179894 @default.
• W2034621471 cites W2155530804 @default.
• W2034621471 cites W2160699421 @default.
• W2034621471 cites W2167185749 @default.
• W2034621471 cites W2169287999 @default.
• W2034621471 cites W2468052951 @default.
• W2034621471 cites W2804551733 @default.
• W2034621471 cites W2133929387 @default.
• W2034621471 doi "https://doi.org/10.1001/jamainternmed.2014.1600" @default.
• W2034621471 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4122627" @default.
• W2034621471 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24887392" @default.
• W2034621471 hasPublicationYear "2014" @default.
• W2034621471 type Work @default.
• W2034621471 sameAs 2034621471 @default.
• W2034621471 citedByCount "34" @default.
• W2034621471 countsByYear W20346214712014 @default.
• W2034621471 countsByYear W20346214712015 @default.
• W2034621471 countsByYear W20346214712016 @default.
• W2034621471 countsByYear W20346214712017 @default.
• W2034621471 countsByYear W20346214712018 @default.
• W2034621471 countsByYear W20346214712019 @default.
• W2034621471 countsByYear W20346214712020 @default.
• W2034621471 countsByYear W20346214712021 @default.
• W2034621471 countsByYear W20346214712023 @default.
• W2034621471 crossrefType "journal-article" @default.
• W2034621471 hasAuthorship W2034621471A5017446229 @default.
• W2034621471 hasAuthorship W2034621471A5024094716 @default.
• W2034621471 hasAuthorship W2034621471A5038373228 @default.
• W2034621471 hasAuthorship W2034621471A5041987495 @default.
• W2034621471 hasAuthorship W2034621471A5049753330 @default.
• W2034621471 hasAuthorship W2034621471A5067413533 @default.
• W2034621471 hasAuthorship W2034621471A5071763026 @default.
• W2034621471 hasAuthorship W2034621471A5071993333 @default.
• W2034621471 hasAuthorship W2034621471A5072330763 @default.
• W2034621471 hasAuthorship W2034621471A5086101616 @default.
• W2034621471 hasBestOaLocation W20346214711 @default.
• W2034621471 hasConcept C121608353 @default.
• W2034621471 hasConcept C126322002 @default.
• W2034621471 hasConcept C126894567 @default.
• W2034621471 hasConcept C143998085 @default.
• W2034621471 hasConcept C207103383 @default.
• W2034621471 hasConcept C2775874879 @default.
• W2034621471 hasConcept C2776235491 @default.
• W2034621471 hasConcept C2778878792 @default.
• W2034621471 hasConcept C2780192828 @default.
• W2034621471 hasConcept C2910366748 @default.
• W2034621471 hasConcept C29456083 @default.
• W2034621471 hasConcept C44249647 @default.
• W2034621471 hasConcept C50382708 @default.
• W2034621471 hasConcept C71924100 @default.
• W2034621471 hasConcept C77350462 @default.
• W2034621471 hasConceptScore W2034621471C121608353 @default.
• W2034621471 hasConceptScore W2034621471C126322002 @default.
• W2034621471 hasConceptScore W2034621471C126894567 @default.
• W2034621471 hasConceptScore W2034621471C143998085 @default.
• W2034621471 hasConceptScore W2034621471C207103383 @default.
• W2034621471 hasConceptScore W2034621471C2775874879 @default.
• W2034621471 hasConceptScore W2034621471C2776235491 @default.
• W2034621471 hasConceptScore W2034621471C2778878792 @default.

• next